Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment

Table 1 Baseline characteristics of RA patients included in the discovery study

Characteristic	Good-responders (n = 50)	Non-responders (n = 20)	p value
Age, mean (SD)	58.1 (13.1)	55.3 (13)	0.42^a
Female, n (%)	31 (62)	15 (75)	0.30^b
Days on drug at outcome, median (IQR)	113 (92, 147)	109 (93, 147)	0.74^c
Baseline DAS28, mean (SD)	5.07 (0.90)	5.09 (0.90)	0.93^a
Concurrent DMARD therapy, n (%)	46 (92)	15 (75)	0.06^b
Swollen joint count, median (IQR)	8 (5, 11)	6 (3, 8)	0.13^c
Tender joint count, median (IQR)	12 (6, 17)	17 (9, 23)	0.15^c
Baseline HAQ score, median (IQR)	1.5 (1, 2.13)	1.8 (1.4, 2.3)	0.21^c

Patients were stratified by EULAR response at 3 months. All patients receiving concurrent DMARD therapy were receiving methotrexate. DAS28 28-joint count disease activity score, DMARD disease modifying anti-rheumatic drugs, HAQ health assessment questionnaire, SD standard deviation, IQR interquartile range. p value: ^atwo-sample t test, ^bchi-squared test, ^cWilcoxon rank-sum test

ISSN: 1478-6362